HRP20120246T1 - Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe - Google Patents
Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe Download PDFInfo
- Publication number
- HRP20120246T1 HRP20120246T1 HR20120246T HRP20120246T HRP20120246T1 HR P20120246 T1 HRP20120246 T1 HR P20120246T1 HR 20120246 T HR20120246 T HR 20120246T HR P20120246 T HRP20120246 T HR P20120246T HR P20120246 T1 HRP20120246 T1 HR P20120246T1
- Authority
- HR
- Croatia
- Prior art keywords
- drug
- amino acids
- disease
- use according
- arthritis
- Prior art date
Links
- 102000044166 interleukin-18 binding protein Human genes 0.000 title 1
- 108010070145 interleukin-18 binding protein Proteins 0.000 title 1
- 101710205006 Interleukin-18-binding protein Proteins 0.000 claims abstract 14
- 102100035017 Interleukin-18-binding protein Human genes 0.000 claims abstract 14
- 150000001413 amino acids Chemical class 0.000 claims abstract 8
- 229920001184 polypeptide Polymers 0.000 claims abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 6
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 125000000524 functional group Chemical group 0.000 claims abstract 2
- 108020001507 fusion proteins Proteins 0.000 claims abstract 2
- 102000037865 fusion proteins Human genes 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 206010067125 Liver injury Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 231100000234 hepatic damage Toxicity 0.000 claims 3
- 230000008818 liver damage Effects 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
Abstract
IL-18BP koji sadrži prvi polipeptid koji se sastoji od amino kiselina 1 do 30 ili od amino kiselina 15 do 30 iz SEQ ID NO: 1 i od drugog polipeptida koji se sastoji od amino kiselina 31 do 164 ili od amino kiselina 31 do 163 iz SEQ ID NO: 1, naznačen time da su prvi i drugi polipeptid vezani sa disulfidnom vezom; ili njihov funkcionalni derivat, fuzionirani protein ili sol, pri čemu se funkcionalni derivat sastoji od barem jedne skupine spojene na jednu ili više funkcionalnih skupina, koje se javljaju kao jedan ili više bočnih lanaca na aminokiselinskim ostatcima. Patent sadrži još 15 patentnih zahtjeva.
Claims (16)
1. IL-18BP koji sadrži prvi polipeptid koji se sastoji od amino kiselina 1 do 30 ili od amino kiselina 15 do 30 iz SEQ ID NO: 1 i od drugog polipeptida koji se sastoji od amino kiselina 31 do 164 ili od amino kiselina 31 do 163 iz SEQ ID NO: 1, naznačen time da su prvi i drugi polipeptid vezani sa disulfidnom vezom; ili njihov funkcionalni derivat, fuzionirani protein ili sol, pri čemu se funkcionalni derivat sastoji od barem jedne skupine spojene na jednu ili više funkcionalnih skupina, koje se javljaju kao jedan ili više bočnih lanaca na aminokiselinskim ostatcima.
2. IL-18BP prema zahtjevu 1, naznačen time da fuzionirani protein sadrži imunoglobulinsko fuzioniranje.
3. IL-18BP prema zahtjevu 1, naznačen time da navedena skupina je polietilen glikol (PEG) skupina.
4. Postupak dobivanja IL-18BP prema zahtjevu 1 ili 2 naznačen time da sadrži korak kultiviranja stanice domaćina koji se sastoji od kodiranja nukleinske kiseline za IL-18BP prema zahtjevima 1 ili 2 kod uvjeta koji su pogodni za ekspresiju navedenog IL-18BP.
5. Postupak dobivanja IL-18BP prema zahtjevu 1 ili 2 naznačen time da sadrži korak izoliranja IL-18BP iz supernatantne stanične kulture stanice domaćina koji se sastoji od kodiranja nukleinske kiseline za IL-18BP prema zahtjevima 1 ili 2.
6. Pripravak koji sadrži IL-18BP naznačen time da je dobiven prema bilo kojem od zahtjeva 1 do 3.
7. Uporaba IL-18 BP prema bilo kojem od zahtjeva 1 do 3, naznačena time da je za dobivanje lijeka za liječenje i/ili sprečavanje bolesti koje su odabrane od: metastaze tumora, psorijaze, artritisa, naročito reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
8. Uporaba prema zahtjevu 7, naznačena time da lijek nadalje sadrži interferon, za istovremenu, slijednu ili odvojenu uporabu.
9. Uporaba prema zahtjevu 8, naznačena time da interferon je interferon-β.
10. Uporaba prema zahtjevu 7, naznačena time da lijek nadalje sadrži inhibitor faktora nekroze tumora (TNF) za istovremenu, slijednu ili odvojenu uporabu.
11. Uporaba prema zahtjevu 10, naznačena time da je inhibitor TNF topivi receptorski TNF.
12. Uporaba prema zahtjevima 7 do 11, naznačena time da IL-18BP se koristi u količini od oko 0.001 do 1000 mg/kg tjelesne težine, ili oko 0.01 do 100 mg/kg tjelesne težine ili oko 0.1 do 10 mg/kg tjelesne težine ili oko 5 mg/kg tjelesne težine.
13. Uporaba prema bilo kojem od zahtjeva 7 do 12, naznačena time da je lijek za subkutano davanje.
14. Uporaba prema bilo kojem od zahtjeva 7 do 12, naznačena time da je lijek za intramuskularno davanje.
15. Uporaba ekspresijskog vektora koji sadrži kodiranje nukleinske kiseline za IL-18BP prema zahtjevu 1 ili 2 naznačena time da je za proizvodnju lijeka za liječenje i/ili sprečavanje bolesti koje su odabrane od: metastaze tumora, psorijaze, artritisa, naročito reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
16. Uporaba stanice koja je genetski modificirana za dobivanje IL-18BP prema zahtjevu 1 ili 2 naznačena time da je za proizvodnju lijeka za liječenje i/ili sprečavanje bolesti koje su odabrane od: metastaze tumora, psorijaze, artritisa, reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03101326 | 2003-05-13 | ||
| PCT/EP2004/005073 WO2004101617A1 (en) | 2003-05-13 | 2004-05-11 | Active variants of the il-18 binding protein and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120246T1 true HRP20120246T1 (hr) | 2012-04-30 |
Family
ID=33442815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120246T HRP20120246T1 (hr) | 2003-05-13 | 2012-03-16 | Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080076708A1 (hr) |
| EP (1) | EP1622939B1 (hr) |
| JP (1) | JP5074030B2 (hr) |
| AT (1) | ATE549353T1 (hr) |
| AU (1) | AU2004238524B2 (hr) |
| CA (1) | CA2524403C (hr) |
| CY (1) | CY1112682T1 (hr) |
| DK (1) | DK1622939T3 (hr) |
| ES (1) | ES2384241T3 (hr) |
| HR (1) | HRP20120246T1 (hr) |
| IL (1) | IL171914A (hr) |
| NO (1) | NO338682B1 (hr) |
| PL (1) | PL1622939T3 (hr) |
| PT (1) | PT1622939E (hr) |
| SI (1) | SI1622939T1 (hr) |
| WO (1) | WO2004101617A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI335336B (hr) * | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| RS50488B (sr) | 2003-03-11 | 2010-03-02 | Laboratoires Serono Sa. | Vektori ekspresije koji sadrže mcmv ie2 promotor |
| PL1675956T3 (pl) | 2003-10-21 | 2011-06-30 | Merck Serono Sa | Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek |
| SI1689777T1 (sl) * | 2003-11-05 | 2007-08-31 | Ares Trading Sa | Postopek za äśiĺ äśenje il-18 vezavnega proteina |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| RS50531B (sr) | 2004-03-01 | 2010-05-07 | Ares Trading S.A. | Upotreba podloge za ćelijsku kulturu bez sadržaja seruma za produkciju il-18bp u ćelijama sisara |
| US7557084B2 (en) | 2004-03-31 | 2009-07-07 | Regeneron Pharmaceuticals, Inc. | IL-18 specific polypeptides and therapeutic uses thereof |
| DE602005009827D1 (de) * | 2004-06-29 | 2008-10-30 | Ares Trading Sa | Verfahren zur aufreinigung von il-18-bindendem protein |
| PL1888100T3 (pl) * | 2005-06-03 | 2012-03-30 | Merck Serono Sa | Zastosowanie lizoform IL-18BP do leczenia i/lub zapobiegania neurologicznym chorobom zapalnym |
| DK1885753T3 (da) * | 2005-06-03 | 2011-10-03 | Ares Trading Sa | Fremstilling af rekombinant II-18-proteiner |
| DK1891088T3 (da) * | 2005-06-10 | 2012-01-30 | Ares Trading Sa | Fremgangsmåde til rensning af et IL-18-bindende protein |
| CN103228290A (zh) | 2011-02-18 | 2013-07-31 | (株)斯坦帝尔 | 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物 |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| WO2015032932A1 (en) * | 2013-09-05 | 2015-03-12 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
| MX2017010919A (es) | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
| US20190070262A1 (en) * | 2017-09-06 | 2019-03-07 | Yale University | Interleukin-18 variants and methods of use |
| US12029778B2 (en) | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| CN114605521A (zh) * | 2022-04-06 | 2022-06-10 | 内蒙古农业大学 | 一种细胞免疫调节蛋白及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| JP4216950B2 (ja) * | 1998-09-01 | 2009-01-28 | 株式会社林原生物化学研究所 | インターロイキン−１８結合蛋白質 |
| KR100537558B1 (ko) * | 1998-09-01 | 2005-12-19 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 인터류킨-18 결합 단백질 |
| RS50926B (sr) | 2000-05-05 | 2010-08-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| UA80676C2 (en) | 2001-01-29 | 2007-10-25 | Applied Research Systems | Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy |
| DK1425028T3 (da) | 2001-05-16 | 2010-03-01 | Yeda Res & Dev | Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis |
| JP4344142B2 (ja) | 2001-05-25 | 2009-10-14 | アレス トレーディング ソシエテ アノニム | Ｃｎｓ損傷の治療または予防のためのｉｌ−１８阻害剤の使用 |
| CA2463020A1 (en) | 2001-10-11 | 2003-04-24 | Applied Research Systems Ars Holding N.V. | Use of gp130 activators in diabetic neuropathy |
| RS50488B (sr) * | 2003-03-11 | 2010-03-02 | Laboratoires Serono Sa. | Vektori ekspresije koji sadrže mcmv ie2 promotor |
| PL1675956T3 (pl) * | 2003-10-21 | 2011-06-30 | Merck Serono Sa | Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek |
| SI1689777T1 (sl) * | 2003-11-05 | 2007-08-31 | Ares Trading Sa | Postopek za äśiĺ äśenje il-18 vezavnega proteina |
| RS50531B (sr) * | 2004-03-01 | 2010-05-07 | Ares Trading S.A. | Upotreba podloge za ćelijsku kulturu bez sadržaja seruma za produkciju il-18bp u ćelijama sisara |
| US7557084B2 (en) * | 2004-03-31 | 2009-07-07 | Regeneron Pharmaceuticals, Inc. | IL-18 specific polypeptides and therapeutic uses thereof |
| DE602005009827D1 (de) * | 2004-06-29 | 2008-10-30 | Ares Trading Sa | Verfahren zur aufreinigung von il-18-bindendem protein |
| DK1885753T3 (da) * | 2005-06-03 | 2011-10-03 | Ares Trading Sa | Fremstilling af rekombinant II-18-proteiner |
| DK1891088T3 (da) * | 2005-06-10 | 2012-01-30 | Ares Trading Sa | Fremgangsmåde til rensning af et IL-18-bindende protein |
-
2004
- 2004-05-11 SI SI200431860T patent/SI1622939T1/sl unknown
- 2004-05-11 PT PT04739182T patent/PT1622939E/pt unknown
- 2004-05-11 US US10/556,417 patent/US20080076708A1/en not_active Abandoned
- 2004-05-11 CA CA2524403A patent/CA2524403C/en not_active Expired - Lifetime
- 2004-05-11 AT AT04739182T patent/ATE549353T1/de active
- 2004-05-11 DK DK04739182.6T patent/DK1622939T3/da active
- 2004-05-11 EP EP04739182A patent/EP1622939B1/en not_active Expired - Lifetime
- 2004-05-11 JP JP2006529792A patent/JP5074030B2/ja not_active Expired - Lifetime
- 2004-05-11 ES ES04739182T patent/ES2384241T3/es not_active Expired - Lifetime
- 2004-05-11 AU AU2004238524A patent/AU2004238524B2/en not_active Expired
- 2004-05-11 WO PCT/EP2004/005073 patent/WO2004101617A1/en active Application Filing
- 2004-05-11 PL PL04739182T patent/PL1622939T3/pl unknown
-
2005
- 2005-11-13 IL IL171914A patent/IL171914A/en active IP Right Grant
- 2005-12-08 NO NO20055838A patent/NO338682B1/no unknown
-
2011
- 2011-03-29 US US13/074,538 patent/US20110189131A1/en not_active Abandoned
-
2012
- 2012-03-16 HR HR20120246T patent/HRP20120246T1/hr unknown
- 2012-04-04 CY CY20121100338T patent/CY1112682T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL171914A (en) | 2013-05-30 |
| CY1112682T1 (el) | 2016-02-10 |
| JP2007535903A (ja) | 2007-12-13 |
| CA2524403A1 (en) | 2004-11-25 |
| PL1622939T3 (pl) | 2012-08-31 |
| WO2004101617A1 (en) | 2004-11-25 |
| SI1622939T1 (sl) | 2012-06-29 |
| AU2004238524B2 (en) | 2011-06-23 |
| CA2524403C (en) | 2013-07-09 |
| ES2384241T3 (es) | 2012-07-02 |
| AU2004238524A1 (en) | 2004-11-25 |
| EP1622939A1 (en) | 2006-02-08 |
| EP1622939B1 (en) | 2012-03-14 |
| DK1622939T3 (da) | 2012-04-10 |
| PT1622939E (pt) | 2012-03-28 |
| IL171914A0 (en) | 2006-04-10 |
| ATE549353T1 (de) | 2012-03-15 |
| US20110189131A1 (en) | 2011-08-04 |
| NO20055838L (no) | 2006-02-13 |
| US20080076708A1 (en) | 2008-03-27 |
| NO338682B1 (no) | 2016-09-26 |
| NO20055838D0 (no) | 2005-12-08 |
| JP5074030B2 (ja) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120246T1 (hr) | Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe | |
| HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
| JP7476467B2 (ja) | 標的化キメラタンパク質及びその使用 | |
| KR100484084B1 (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| US10808019B2 (en) | Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands | |
| Sherry et al. | Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. | |
| ES2317843T3 (es) | Proteinas de fusion de eritropoyetina-inmunoglobulina. | |
| US20240100129A1 (en) | Serum Albumin-Binding Fibronectin Type III Domains | |
| JP2014523238A5 (hr) | ||
| CN107847583A (zh) | 用于治疗癌症的聚乙二醇化白细胞介素‑10 | |
| CA2993891A1 (en) | Interleukin-15 fusion proteins for tumor targeting therapy | |
| KR20160079776A (ko) | 변형된 치료제 및 이의 조성물 | |
| US20220275048A1 (en) | Dimer immunoadhesin, pharmaceutical compostion and use thereof | |
| CN106913865A (zh) | 使用白细胞介素‑10治疗疾病和病症的方法 | |
| JP2013513377A5 (hr) | ||
| CN110573532A (zh) | TGF-β受体胞外域融合分子及其用途 | |
| TW201138808A (en) | Serum albumin binding molecules | |
| WO2008063113A8 (en) | Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf | |
| JP2007521807A5 (hr) | ||
| CN104211800A (zh) | 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体 | |
| CN109810198A (zh) | 利用免疫球蛋白片段的位点特异性glp-2缀合物 | |
| TWI691512B (zh) | Ｆｃ融合高親和性ＩｇＥ受體α鏈 | |
| JP2008521426A5 (hr) | ||
| CN106573072A (zh) | 降低血清胆固醇的方法 | |
| CN102421447A (zh) | 用peg标记干扰素的方法 |